Objective:

To report on the FDA approval of deucravacitinib for the treatment of adults with active psoriatic arthritis.

Approach:

Key Findings:

• Deucravacitinib achieved ACR20 response in 54% of patients in both trials compared to 34% and 39% in placebo groups.
• ACR50 responses were 24% vs 14% and 29% vs 16% for deucravacitinib vs placebo in the two trials respectively.
• ACR70 responses were 12% vs 5% and 10% vs 5% for deucravacitinib vs placebo.
• Minimal disease activity was achieved by a greater proportion of patients receiving deucravacitinib.

Interpretation:

Deucravacitinib is the first TYK2 inhibitor approved for psoriatic arthritis, showing significant efficacy in improving disease activity compared to placebo.

Limitations:

• The trials included only adults aged 18 years or older with active PsA.
• POETYK PsA-1 participants had not previously received biologic DMARDs, while POETYK PsA-2 included patients with prior TNF inhibitor exposure.

Conclusion:

Deucravacitinib represents a new therapeutic option for adults with active psoriatic arthritis, demonstrating improved outcomes in clinical trials.

Sources:

• Bristol Myers Squibb
Source

Based on findings from:

​​​​​​​PsA Treatment Options Expand

Kathryn Wighton. MDSpire News, 2026.

https://news.mdspire.com/rheumatology/articles/psa-treatment-options-expand/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.